卡培他滨+放疗共同治疗局部进展期直肠癌患者的临床分析

Clinical Analysis of Capecitabine Plus Radiotherapy in the Treatment of Patients with Locally Advanced Rectal Cancer

目的分析局部进展期直肠癌患者应用卡培他滨+放疗共同治疗的临床效果。方法便利抽取2014年9月-2016年9月期间78例局部进展期直肠癌患者研究,根据患者病床单双号分组,单一组(39例,单号,采取放疗治疗)、联合组(39例,双号,采取卡培他滨+放疗共同治疗),比较临床近期疗效、不良反应发生率、治疗后CEA水平、PFS时间、复发率及生存率。结果联合组近期疗效、2年生存率92.31%、89.74%高于单一组74.36%、66.67%,复发率7.69%低于对照组25.64%,差异有统计学意义(P<0.05),联合组不良反应发生率为15.38%,单一组发生率为12.82%,差异无统计学意义(χ^2=0.106,P>0.05),予以患者对症治疗后,所有患者症状均自行缓解,联合组治疗后CEA水平低于单一组,PFS时间长于单一组,差异有统计学意义(P<0.05)。结论卡培他滨联合放疗对局部进展期直肠癌患者治疗,成效高,值得推广。

Objective To analyze the clinical effects of capecitabine plus radiotherapy in patients with locally advanced rectal cancer.Methods A total of 78 patients with locally advanced rectal cancer from September 2014 to September 2016 were conveniently selected.According to the patient's disease sheet,the single group (39 cases,single number,radiotherapy) and the combined group (39 cases,double number,taking capecitabine + radiotherapy together,compare clinical short-term efficacy,incidence of adverse reactions,post-treatment CEA levels,PFS time,recurrence rate and survival rate.Results The short-term efficacy,2-year survival rate of the combined group was 92.31%,89.74% higher than the single group 74.36%,66.67%,the recurrence rate was 7.69% lower than the control group 25.64%,the difference were statistically significant(P<0.05),combined group adverse reactions incidence rate was 15.38%,the incidence rate of single group was 12.82%,and there was no statistically significant difference (χ^2=0.106,P>0.05).After symptomatic treatment,the symptoms of all patients were relieved by themselves,and the CEA level was low after treatment in the combined group.In the single group,the PFS time was longer than the single group,and the difference was statistically significant(P<0.05).Conclusion Capecitabine combined with radiotherapy is effective in the treatment of patients with locally advanced rectal cancer and is worthy of promotion.